Wednesday, July 8, 2026
🇺🇸 FDA

Patent directory · USPTO A61K / A61P

Patents matching “Corcept Therapeutics Incorporated”

120 pharma patents match "Corcept Therapeutics Incorporated" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 120
Index total 30,257
Page 5 / 5

Quick answer

This filtered view shows 120 pharmaceutical patents matching "Corcept Therapeutics Incorporated" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

120 results for “Corcept Therapeutics Incorporated” · 30,257 patents in full index Clear search

  1. US 8859774

    Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators

    Corcept Therapeutics Incorporated · Granted Oct 14, 2014 · Expires Oct 9, 2034

    granted

  2. US 8829024

    Combination steroid and glucocorticoid receptor antagonist therapy

    Corcept Therapeutics Incorporated · Granted Sep 9, 2014 · Expires Sep 4, 2034

    granted

  3. US 8741880

    Antiglucocorticoid therapy for the prevention of neurological damage in premature infants

    Corcept Therapeutics Incorporated · Granted Jun 3, 2014 · Expires May 29, 2034

    granted

  4. US 8685973

    Pyrimidine cyclohexyl glucocorticoid receptor modulators

    Corcept Therapeutics Incorporated · Granted Apr 1, 2014 · Expires Mar 27, 2034

    granted

  5. US 8598154

    Pyridyl-amine fused azadecalin modulators

    Corcept Therapeutics Incorporated · Granted Dec 3, 2013 · Expires Nov 28, 2033

    granted

  6. US 8598149

    Optimizing mifepristone levels in plasma serum of patients suffering from mental disorders treatable with glucocorticoid receptor antagonists

    Corcept Therapeutics Incorporated · Granted Dec 3, 2013 · Expires Nov 28, 2033

    granted

  7. US 8557839

    Fused ring azadecalin glucocorticoid receptor modulators

    Corcept Therapeutics Incorporated · Granted Oct 15, 2013 · Expires Oct 10, 2033

    granted

  8. US 8476254

    Methods for treating psychosis associated with interferson-α therapy

    Corcept Therapeutics Incorporated · Granted Jul 2, 2013 · Expires Jun 27, 2033

    granted

  9. US 8461172

    Solid forms and process for preparing

    Corcept Therapeutics Incorporated · Granted Jun 11, 2013 · Expires Jun 6, 2033

    granted

  10. US 8450379

    Methods for treating migraine

    Corcept Therapeutics Incorporated · Granted May 28, 2013 · Expires May 23, 2033

    granted

  11. US 8324203

    Azadecalin glucocorticoid receptor modulators

    Corcept Therapeutics Incorporated · Granted Dec 4, 2012 · Expires Nov 29, 2032

    granted

  12. US 8173664

    Modified pyrimidine glucocorticoid receptor modulators

    Corcept Therapeutics Incorporated · Granted May 8, 2012 · Expires May 3, 2032

    granted

  13. US 8097606

    Antiglucocorticoids for the treatment of catatonia

    Corcept Therapeutics Incorporated · Granted Jan 17, 2012 · Expires Jan 12, 2032

    granted

  14. US 7928237

    Fused ring azadecalin glucocorticoid receptor modulators

    Corcept Therapeutics Incorporated · Granted Apr 19, 2011 · Expires Apr 14, 2031

    granted

  15. US 7884091

    Methods for treating delirium using glucocorticoid receptor-specific antagonists

    Corcept Therapeutics Incorporated · Granted Feb 8, 2011 · Expires Feb 3, 2031

    granted

  16. US 7678813

    Azadecalin Glucocorticoid receptor modulators

    Corcept Therapeutics Incorporated · Granted Mar 16, 2010 · Expires Mar 11, 2030

    granted

  17. US 7576076

    Modified pyrimidine glucocorticoid receptor modulators

    Corcept Therapeutics Incorporated · Granted Aug 18, 2009 · Expires Aug 13, 2029

    granted

  18. US 7402578

    Methods for inhibiting cognitive deterioration in adults with down's syndrome

    Corcept Therapeutics Incorporated · Granted Jul 22, 2008 · Expires Jul 17, 2028

    granted

  19. US 7361646

    Methods for treating gastroesophageal reflux disease

    Corcept Therapeutics Incorporated · Granted Apr 22, 2008 · Expires Apr 17, 2028

    granted

  20. US 7326697

    Methods for increasing the therapeutic response to electroconvulsive therapy

    Corcept Therapeutics Incorporated · Granted Feb 5, 2008 · Expires Jan 31, 2028

    granted

  21. US 7163934

    Methods for treating delirium glucocorticoid receptor-specific antagonists

    Corcept Therapeutics Incorporated · Granted Jan 16, 2007 · Expires Jan 11, 2027

    granted

  22. US 6964953

    Methods for treating stress disorders using glucocorticoid receptor-specific antagonists

    Corcept Therapeutics Incorporated · Granted Nov 15, 2005 · Expires Nov 10, 2025

    expired

  23. US 6680310

    Methods for preventing antipsychotic-induced weight gain

    Corcept Therapeutics Incorporated · Granted Jan 20, 2004 · Expires Jan 15, 2024

    expired

  24. US 6620802

    Methods of treating mild cognitive impairment using a glucocorticoid-specific receptor antagonist

    Corcept Therapeutics Incorporated · Granted Sep 16, 2003 · Expires Sep 11, 2023

    expired

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.